Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Pyelonephritis pipeline market research report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects.

Key Targets in the Pyelonephritis Pipeline Market

The key targets in the Pyelonephritis pipeline market are Beta Lactamase, Penicillin Binding Protein, 16S Ribosomal RNA, DNA Gyrase, DNA Topoisomerase II, DNA Topoisomerase IV, and Penicillin Binding Protein 1B. Beta Lactamase has the highest pipeline products.

Pyelonephritis Pipeline Market, by Targets

Pyelonephritis Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA types in the Pyelonephritis Pipeline Market

The key MoA types in the Pyelonephritis pipeline market are Beta Lactamase Inhibitor, Penicillin Binding Protein Inhibitor, 16S Ribosomal RNA Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase II Inhibitor, DNA Topoisomerase IV Inhibitor, Penicillin Binding Protein 1B Inhibitor, Penicillin Binding Protein 1C Inhibitor, Penicillin Binding Protein 2 Inhibitor, Penicillin Binding Protein 3 Inhibitor, and Peptidoglycan Inhibitor. Beta Lactamase Inhibitor has the highest pipeline products.

Pyelonephritis Pipeline Market, by MoA

Pyelonephritis Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA types in the Pyelonephritis Pipeline Market

The key RoA types in the Pyelonephritis pipeline market are intravenous, oral, parenteral, auricular (Otic), and intravenous drip. Intravenous has the highest pipeline products.

Pyelonephritis Pipeline Market, by RoA

Pyelonephritis Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Pyelonephritis Pipeline Market

The key molecule type in the Pyelonephritis pipeline market is small molecule.

Key Companies in the Pyelonephritis Pipeline Market

The key companies in the Pyelonephritis pipeline market are Meiji Seika Pharma Co Ltd, Wockhardt Ltd, Achaogen Inc (Inactive), Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, and Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd. Meiji Seika Pharma Co Ltd has the highest pipeline products.

Pyelonephritis Pipeline Market, by Companies

Pyelonephritis Pipeline Market, by Companies

To know more about key companies, download a free report sample

Market report overview

Key targets Beta Lactamase, Penicillin Binding Protein, 16S Ribosomal RNA, DNA Gyrase, DNA Topoisomerase II, DNA Topoisomerase IV, and Penicillin Binding Protein 1B
Key MoA types Beta Lactamase Inhibitor, Penicillin Binding Protein Inhibitor, 16S Ribosomal RNA Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase II Inhibitor, DNA Topoisomerase IV Inhibitor, Penicillin Binding Protein 1B Inhibitor, Penicillin Binding Protein 1C Inhibitor, Penicillin Binding Protein 2 Inhibitor, Penicillin Binding Protein 3 Inhibitor, and Peptidoglycan Inhibitor
Key RoA types Intravenous, Oral, Parenteral, Auricular (Otic), and Intravenous Drip
Key Molecule Type Small Molecule
Key Companies Meiji Seika Pharma Co Ltd, Wockhardt Ltd, Achaogen Inc (Inactive), Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, and Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Achaogen Inc (Inactive)
Allecra Therapeutics GmbH
Entasis Therapeutics Holdings Inc
Iterum Therapeutics Plc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
Pfizer Inc
Qilu Pharmaceutical Co Ltd
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
XuanZhu Biological Technology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pyelonephritis – Overview

Pyelonephritis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pyelonephritis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pyelonephritis – Companies Involved in Therapeutics Development

Achaogen Inc (Inactive)

Allecra Therapeutics GmbH

Entasis Therapeutics Holdings Inc

Iterum Therapeutics Plc

Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Nabriva Therapeutics Plc

Paratek Pharmaceuticals Inc

Pfizer Inc

Qilu Pharmaceutical Co Ltd

VenatoRx Pharmaceuticals Inc

Wockhardt Ltd

XuanZhu Biological Technology Co Ltd

Pyelonephritis – Drug Profiles

(AAI-101 + cefepime) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(avibactam sodium + ceftazidime) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(cefepime + taniborbactam hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(cefepime + zidebactam) – Drug Profile

Product Description

Mechanism Of Action

(ceftolozane sulfate + tazobactam sodium) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(durlobactam sodium + sulbactam) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(meropenem + vaborbactam) – Drug Profile

Product Description

Mechanism Of Action

History of Events

benapenem – Drug Profile

Product Description

Mechanism Of Action

History of Events

ceforanide – Drug Profile

Product Description

Mechanism Of Action

finafloxacin – Drug Profile

Product Description

Mechanism Of Action

History of Events

FL-058 – Drug Profile

Product Description

Mechanism Of Action

History of Events

fosfomycin disodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

nacubactam – Drug Profile

Product Description

Mechanism Of Action

History of Events

omadacycline tosylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

plazomicin sulfate – Drug Profile

Product Description

Mechanism Of Action

History of Events

sulopenem – Drug Profile

Product Description

Mechanism Of Action

History of Events

tebipenem pivoxil hydrobromide – Drug Profile

Product Description

Mechanism Of Action

History of Events

WCK-6777 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Pyelonephritis – Dormant Projects

Pyelonephritis – Discontinued Products

Pyelonephritis – Product Development Milestones

Featured News & Press Releases

Apr 06, 2022: Spero Therapeutics tebipenem pivoxil hydrobromide phase 3 data published in The New England Journal of Medicine

Jan 03, 2022: Spero Therapeutics announces FDA acceptance and Priority Review of New Drug Application for Tebipenem HBr for the treatment of complicated urinary tract infections including pyelonephritis

Oct 28, 2021: Spero Therapeutics submits new drug application to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections including pyelonephritis

Sep 16, 2021: Spero Therapeutics to present data at IDWeek 2021

Dec 16, 2020: Class 2 medicines recall: Merck Sharp & Dohme, Zerbaxa 1g/0.5g powder for concentrate for solution for infusion

Oct 21, 2020: Key highlights include data on NUZYRA as an alternative to standard of care to reduce clostridioides difficile infections and real-world experience with NUZYRA for nontuberculous mycobacterial and MDR/XDR gram negative infections

Oct 16, 2020: Spero Therapeutics to present data on tebipenem HBr at IDWeek 2020

Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta

Sep 08, 2020: Spero Therapeutics announces positive topline results from its phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis

Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta

Apr 20, 2020: Wockhardt receives US FDA Qualified Infectious Disease Product designation for WCK 6777, a first ever once-a-day ß-lactam enhancer class antibiotic

Feb 25, 2020: Allecra Therapeutics announces positive top-line results for Phase 3 ALLIUM clinical trial of EXBLIFEP for complicated urinary tract infections

Sep 03, 2019: Allecra Therapeutics to present data at ASM/ESCMID 2019 Conference on drug development to meet the challenge of antimicrobial resistance

Jul 29, 2019: Merck receives positive EU CHMP opinion for ZERBAXA 3g dose (ceftolozane and tazobactam) for the treatment of adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)

Apr 15, 2019: Paratek Pharmaceuticals broadens clinical profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Pyelonephritis, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pyelonephritis – Pipeline by Achaogen Inc (Inactive), 2022

Pyelonephritis – Pipeline by Allecra Therapeutics GmbH, 2022

Pyelonephritis – Pipeline by Entasis Therapeutics Holdings Inc, 2022

Pyelonephritis – Pipeline by Iterum Therapeutics Plc, 2022

Pyelonephritis – Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2022

Pyelonephritis – Pipeline by Meiji Seika Pharma Co Ltd, 2022

Pyelonephritis – Pipeline by Melinta Therapeutics Inc, 2022

Pyelonephritis – Pipeline by Merck & Co Inc, 2022

Pyelonephritis – Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022

Pyelonephritis – Pipeline by Nabriva Therapeutics Plc, 2022

Pyelonephritis – Pipeline by Paratek Pharmaceuticals Inc, 2022

Pyelonephritis – Pipeline by Pfizer Inc, 2022

Pyelonephritis – Pipeline by Qilu Pharmaceutical Co Ltd, 2022

Pyelonephritis – Pipeline by VenatoRx Pharmaceuticals Inc, 2022

Pyelonephritis – Pipeline by Wockhardt Ltd, 2022

Pyelonephritis – Pipeline by XuanZhu Biological Technology Co Ltd, 2022

Pyelonephritis – Dormant Projects, 2022

Pyelonephritis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Pyelonephritis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Pyelonephritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.